A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

NCT07498465 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped Other - Protocol moved to Withdrawn

Conditions

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Childhood Acute Lymphoblastic Leukemia
Childhood Acute Myeloid Leukemia
Childhood Mixed Phenotype Acute Leukemia
Mixed Phenotype Acute Leukemia

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Cytarabine
PROCEDURE: Echocardiography Test
DRUG: Methotrexate
PROCEDURE: Radiologic Examination
DRUG: Revumenib
DRUG: Therapeutic Hydrocortisone

Sponsor

Children's Oncology Group